Acasti Pharma Inc - ACST EV/Sales Multiple

Public company logo of Acasti Pharma Inc (ACST)

High risks stemming from a lack of commercial products and a dependence on external financing are putting pressure on the capital of Acasti Pharma (ACST). The EV-to-revenue multiple confirms this volatility, where the metric determines this level. Prospects rely on the development of non-opioid analgesics for cardiac pathologies, while the environmental profile is based on a fabless development model that minimizes ecological impact.

Acasti Pharma Inc. - ACST Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

Acasti Pharma - analytical breakdowns and key metrics (ACST)

Fundamental company valuation:Acasti Pharma
Mass-produced product of Acasti

This ratio determines the market value of the business, accounting for net debt relative to sales volume, which allows for the identification of asset overvaluation independent of the credit load. Analyzing the enterprise value-to-revenue ratio for Acasti Pharma (ACST) is critically important, as the commercialization of orphan drugs for the treatment of neurological pathologies directly impacts the company's fundamental stability and investment attractiveness.